➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
McKinsey
Mallinckrodt
Harvard Business School
Moodys

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ATOVAQUONE; PROGUANIL HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Atovaquone; Proguanil Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00084227 ↗ Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America Completed Pfizer Phase 2/Phase 3 2004-07-01 The primary objective is to confirm the hypothesis that azithromycin plus chloroquine is non-inferior to atovaquone-proguanil for the treatment of symptomatic, uncomplicated malaria due to P. falciparum.
NCT00149383 ↗ Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria Completed McLaughlin-Rotman Center for Global Health, University of Toronto Phase 1/Phase 2 2004-12-01 The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive rosiglitazone in the treatment of uncomplicated P.falciparum malaria.
NCT00149383 ↗ Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria Completed Mahidol University Phase 1/Phase 2 2004-12-01 The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive rosiglitazone in the treatment of uncomplicated P.falciparum malaria.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Atovaquone; Proguanil Hydrochloride

Condition Name

Condition Name for Atovaquone; Proguanil Hydrochloride
Intervention Trials
Malaria 12
Falciparum Malaria 2
Falciparum 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Atovaquone; Proguanil Hydrochloride
Intervention Trials
Malaria 16
Malaria, Falciparum 6
Toxoplasmosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Atovaquone; Proguanil Hydrochloride

Trials by Country

Trials by Country for Atovaquone; Proguanil Hydrochloride
Location Trials
Netherlands 5
Thailand 3
United States 3
Cambodia 2
Japan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Atovaquone; Proguanil Hydrochloride
Location Trials
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Atovaquone; Proguanil Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Atovaquone; Proguanil Hydrochloride
Clinical Trial Phase Trials
Phase 4 8
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Atovaquone; Proguanil Hydrochloride
Clinical Trial Phase Trials
Completed 13
Recruiting 4
Not yet recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Atovaquone; Proguanil Hydrochloride

Sponsor Name

Sponsor Name for Atovaquone; Proguanil Hydrochloride
Sponsor Trials
Radboud University 3
Medicines for Malaria Venture 3
Richmond Pharmacology Limited 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Atovaquone; Proguanil Hydrochloride
Sponsor Trials
Other 27
Industry 8
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
Dow
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.